Along with the slew of RNA-related news that dropped on Jan. 13, cash-rich Moderna Therapeutics LLC announced that it has landed a partnership with Alexion Pharmaceuticals Inc. for its preclinical rare disease messenger-RNA program. The deal marks another vote of confidence in the technology and solidifies Moderna’s place as a leader in the space.
Moderna Scores Another Cash-Rich Partnership For Its Preclinical Work
The mRNA-focused company has inked a deal with Alexion for its work in rare diseases, promising plenty of cash in its future and further validation of its technology.